First Thing, Daily Maverick's flagship newsletter

Join the 230 000 South Africans who read First Thing newsletter.

We'd like our readers to start paying for Daily Maverick

More specifically, we'd like those who can afford to pay to start paying. What it comes down to is whether or not you value Daily Maverick. Think of us in terms of your daily cappuccino from your favourite coffee shop. It costs around R35. That’s R1,050 per month on frothy milk. Don’t get us wrong, we’re almost exclusively fuelled by coffee. BUT maybe R200 of that R1,050 could go to the journalism that’s fighting for the country?

We don’t dictate how much we’d like our readers to contribute. After all, how much you value our work is subjective (and frankly, every amount helps). At R200, you get it back in Uber Eats and ride vouchers every month, but that’s just a suggestion. A little less than a week’s worth of cappuccinos.

We can't survive on hope and our own determination. Our country is going to be considerably worse off if we don’t have a strong, sustainable news media. If you’re rejigging your budgets, and it comes to choosing between frothy milk and Daily Maverick, we hope you might reconsider that cappuccino.

We need your help. And we’re not ashamed to ask for it.

Our mission is to Defend Truth. Join Maverick Insider.

Support Daily Maverick→
Payment options

Pfizer signs new $3.2 bln Covid-19 vaccine deal with U....

Covid-19

COVID-19

Pfizer signs new $3.2 bln Covid-19 vaccine deal with U.S. government

A vial of Pfizer's Covid-19 vaccine for children 6 months to 5 years old. EPA-EFE/JUSTIN LANE
By Reuters
30 Jun 2022 0

June 29 (Reuters) - Pfizer Inc PFE.N and partner BioNTech SE 22UAy.DE said on Wednesday they signed a $3.2 billion deal with the U.S. government for 105 million doses of their COVID-19 vaccine, which could be delivered as soon as later this summer.

The deal includes supplies of a retooled Omicron-adapted vaccine, pending regulatory clearance, according to Pfizer.

Drugmakers have been developing vaccines to target the Omicron variant that became dominant last winter.

The average price per dose in the new deal is over $30, a more than 50% increase from the $19.50 per dose the U.S. government paid in its initial contract with Pfizer.

Some of the vaccine earmarked for adults included in the contract will be in single-dose vials, which are more expensive to manufacture but reduce waste of unused shots from open vials.

“We look forward to taking delivery of these new variant-specific vaccines and working with state and local health departments, pharmacies, healthcare providers, federally qualified health centers, and other partners to make them available in communities around the country this fall,” U.S. Health and Human Services (HHS) official Dawn O’Connell said in a statement.

Advisers to the U.S. Food and Drug Administration on Tuesday recommended a change in the design of COVID-19 booster shots for this fall in order to combat more recently circulating variants of the coronavirus.

The U.S. government also has the option to purchase up to 195 million additional doses, bringing the total number of potential doses to 300 million, the companies said.

The new contract should boost 2022 vaccine sales for Pfizer and BioNTech, which share profits from the shots. Pfizer has forecast COVID-19 vaccine sales of $32 billion this year. Analysts, on average, have forecast 2022 sales of around $33.6 billion for the shots.

The U.S. government has distributed close to 450 million doses of the Pfizer/BioNTech vaccine in the United States since it was first authorized in December 2020, according to data from the U.S. Centers for Disease Control and Prevention. Over 350 million of those doses have been administered.

Because the Biden administration was unable to line up more COVID-19 funding from Congress earlier this month, it was forced to reallocate $10 billion of existing funding to pay for additional vaccines and treatments.

According to HHS, the money to pay for doses in this new contract comes from that funding.

By Manas Mishra and Michael Erman

(Reporting by Manas Mishra in Bengaluru and Michael Erman in New York; Editing by Shounak Dasgupta and Bill Berkrot)

Gallery

"Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]"

Please peer review 3 community comments before your comment can be posted